2-fluorobenzyl methyl sulfide | 155853-27-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-fluorobenzyl methyl sulfide
• 英文别名: 1-fluoro-2-(methylsulfanylmethyl)benzene
• CAS: 155853-27-3
• 化学式: C₈H₉FS
• mdl: MFCD23143127
• 分子量: 156.224
• InChiKey: FOGHZMQAJSGQEZ-UHFFFAOYSA-N

物化性质

• 沸点：
  200.2±15.0 °C(Predicted)
• 密度：
  1.112±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 储存条件：
  室温

反应信息

• 作为产物：
  描述：

  2-氟溴苄 、 sodium thiomethoxide 生成 2-fluorobenzyl methyl sulfide
  参考文献：
  名称：

  Azetidine derivatives, their preparation and medicaments containing them

  摘要：

  本发明涉及通式(1)的化合物，其中：R代表链(A)或(B)；R1是甲基或乙基；R2是可任选取代的芳香环或可任选取代的杂芳香环；R3和R4，相同或不同，是可任选取代的芳香环或可任选取代的杂芳香环；R′代表氢原子或—CO—烷基，它们的光学异构体，它们的盐，它们的制备方法以及含有它们的药物。

  公开号：

  US20020035102A1

文献信息

• Inhibitors of c-Jun N-terminal kinases
  申请人：Liu Gang

  公开号：US20060173050A1

  公开（公告）日：2006-08-03

  The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

  本发明涉及作为c-jun N-末端激酶1、2或3（JNK1、JNK2或JNK3）抑制剂的化合物，包含这些化合物的组合物以及这些化合物在预防或治疗由JNK1、JNK2和JNK3激活调控的疾病中的用途。
• HALOALKYLSULFONANILIDE DERIVATIVE
  申请人：Kai Masanori

  公开号：US20120029187A1

  公开（公告）日：2012-02-02

  Novel herbicides are provided. A haloalkylsulfonanilide derivative represented by the formula (1) or an agrochemically acceptable salt thereof: the formula (1): wherein Z is —C(R 9 )(R 10 )— or —N(R 11 )—, A is an oxygen atom, a sulfur atom or —N(R 12 )—, W is an oxygen atom or a sulfur atom, m is an integer of from 0 to 3, n is an integer of from 0 to 3, m+n is from 1 to 3, R 1 is halo C 1 -C 6 alkyl, R 2 is a hydrogen atom, C 1 -C 6 alkyl or the like, each of R 3 and R 4 is independently a hydrogen atom, C 1 -C 6 alkyl or the like, each of R 5 , R 6 , R 7 , R 8 , R 9 and R 10 is independently a hydrogen atom, a halogen, C 1 -C 6 alkyl or the like, each of R 11 and R 12 is a hydrogen atom, C 1 -C 6 alkyl, halo C 1 -C 6 alkyl or the like, and X is independently a hydrogen atom, a halogen, C 1 -C 6 alkyl, or the like.

  提供新型除草剂。 一种由式（1）表示的卤烷基磺酰苯胺衍生物或其农药可接受的盐： 式（1）： 其中Z为—C(R9)(R10)—或—N(R11)—，A为氧原子、硫原子或—N(R12)—，W为氧原子或硫原子，m为0至3的整数，n为0至3的整数，m+n为1至3，R1为卤代C1-C6烷基，R2为氢原子、C1-C6烷基或类似物，R3和R4中的每一个独立地为氢原子、C1-C6烷基或类似物，R5、R6、R7、R8、R9和R10中的每一个独立地为氢原子、卤素、C1-C6烷基或类似物，R11和R12中的每一个为氢原子、C1-C6烷基、卤代C1-C6烷基或类似物，X独立地为氢原子、卤素、C1-C6烷基或类似物。
• Pyrimidine derivatives as ghrelin receptor modulators
  申请人：Kosogof Christi

  公开号：US20050070712A1

  公开（公告）日：2005-03-31

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus.

  本发明涉及式(I)的化合物，或者其治疗上适宜的盐或前药，该化合物的制备、含有该化合物的组合物以及在预防或治疗由生长激素释放素调节的疾病中使用该化合物，包括厌食症、癌症恶病质、进食障碍、与年龄相关的身体组成下降、体重增加、肥胖和糖尿病。
• Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
  申请人：Kosogof Christi

  公开号：US20050171131A1

  公开（公告）日：2005-08-04

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.

  本发明涉及式(I)的化合物，或其治疗上适用的盐或前药，所述化合物的制备，含有所述化合物的组合物以及在预防或治疗由胃泌素受体调节的疾病中使用所述化合物，包括普拉德-威利综合征、进食障碍、体重增加、饮食和锻炼后体重减轻维持、肥胖，以及与肥胖相关的疾病，如非胰岛素依赖型糖尿病。
• [EN] HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES CONTENANT UN HALOALKYLE UTILISE COMME INHIBITEURS DE CYSTEINE PROTEASE
  申请人：AXYS PHARM INC

  公开号：WO2005028454A1

  公开（公告）日：2005-03-31

  The application is directed to haloalkyl-substituted compounds of Formula (I), wherein R1, R1a, R2, R3, R4’ and E are as defined in the claims. The compounds are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. Pharmaceutical compositions comprising these compounds and their use are also disclosed.

  该应用程序针对式(I)的卤代烷基取代化合物，其中R1、R1a、R2、R3、R4'和E如索权中所定义。这些化合物是半胱氨酸蛋白酶的抑制剂，特别是卡托普斯蛋白酶B、K、L、F和S，因此可用于治疗由这些蛋白酶介导的疾病。还公开了包含这些化合物的药物组合物及其用途。